• shenzhen salubris pharmaceuticals co., ltd. was established on november 3rd, 1998 in shenzhen, china.

  • production of the first product xindakang (azithromycin dispersible tablets) started.

  • production of the first powder injection product xinlixin (cefuroxime sodium for injection) started.

  • taijia (clopidogrel bisulfate tablets) started production, and was listed as shenzhen high-tech project.

  • the api facility was established and put into production

  • salubris was rewarded as a “national high-tech enterprise”.

  • the salubris (shandong) production base for intermediates and apis was established.

  • shenzhen salubris pharmaceuticals co., ltd. was successfully listed on the shenzhen stock exchange.

  • salubris was certified as “key high-tech enterprise of national torch program”.

  • tsinghua university - salubris joint research center for small molecule drugs was set up.

  • the salubris (pingshan) industrial base for medical devices and finished medicinal products was established.

  • salubris technology center was assessed as “national level industrial technology center”.

  • the salubris (dayawan) production base for oral dosage formulation and chemical apis was established.

  • shenzhen post-doctoral innovative practice base (municipal level) was founded.

  • allisartan isoproxil tablets (xinlitan) was awarded as “top 10 blockbuster prescription drugs in 2013 in china”

  • the production base of genemen biotech (suzhou) co., ltd. joined in salubris.

  • the r&d base of genekey biotech (chengdu) co., ltd. joined in salubris

  • the propaganda film of salubris was on display on times square, new york

  • salubris acquired shenzhen keyidun biomedical technology co., ltd.

  • taijia® received chinese patent gold award.

  • salubris started strategic alliance with the national key biotherapy laboratory of sichuan university for innovative drugs.

  • salubris acquired alain medical (beijing) co., ltd.

  • salubris received the award of “national demonstration enterprise in technology innovation”.

  • salubris solely financed the “whole-hearted care” program, covering the whole-process management on medication donation for patients with acute coronary syndrome (acs).

  • taijia was approved and on the list of products by quality consistency evaluation(qce).

  • genemen biotech (suzhou) co., ltd was equipped with production plat of flex factory.

  • salubris biotherapeutics, inc. was founded in the united states.

  • xinlitan (allisartan isoproxil tablets) was included in the national reimbursement drugs list.

  • salubris invested in go therapeutics, inc.

网站地图